Targeted drug can ‘diminish the suffering’ of myelofibrosis

30 mayo 2015

Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a researcher who co-led PERSIST-1, the worldwide phase 3 clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/lB2s5oqwwvY/150530102212.htm

Volver